Team:Goettingen/Achievement
From 2013.igem.org
(→About our parts) |
|||
(11 intermediate revisions not shown) | |||
Line 6: | Line 6: | ||
</div> | </div> | ||
<br /> | <br /> | ||
+ | |||
+ | |||
+ | <img src="https://static.igem.org/mediawiki/2013/6/66/Goe-qNav.png" style="position: fixed;z-index: 199;bottom: 11%;right: 2.5%;_position: absolute;_top: expression(documentElement.scrollTop + documentElement.clientHeight-this.offsetHeight);cursor: pointer;opacity: 0.5;-moz-opacity: 0.5;-khtml-opacity: 0.5;-filter: alpha(opacity = 50 );" onclick="toggle(this.nextElementSibling || getnextElementSibling(this))" /> | ||
+ | <div style="position: fixed;z-index: 199;bottom: 19%;right: 2.5%;_position: absolute;_top: expression(documentElement.scrollTop + documentElement.clientHeight-this.offsetHeight);cursor: pointer;display: none;background: #fff;border: 1px solid #A3A3A3;padding: 20px; | ||
+ | border-radius: 5px;"> | ||
+ | <b>Achievements:</b><br /> | ||
+ | <ul> | ||
+ | <li><a href="#Team:.09Goettingen">Team profile</a></li> | ||
+ | <li><a href="#Achievements">Our achievements</a></li> | ||
+ | <li><a href="#We_apply_for">We apply for:</a></li> | ||
+ | <li><a href="#About_our_parts">About our parts</a></li> | ||
+ | </ul> | ||
+ | </div> | ||
+ | |||
+ | |||
<div id="body"> | <div id="body"> | ||
</html> | </html> | ||
Line 24: | Line 39: | ||
'''Project Abstract:''' | '''Project Abstract:''' | ||
- | Since the discovery of penicillin by Alexander Fleming in 1928, antibiotics have marked a major victory of mankind in the battle against infectious diseases. However, after 90 years, the antibiotics are now losing their old time glory: Bacteria acquire resistance against antibiotics and become unbridled. We must control the use of antibiotics, meanwhile, we need new antibiotics, which can sufficiently eliminate the invaders without hurting the "good" bacteria. Therefore, | + | Since the discovery of penicillin by Alexander Fleming in 1928, antibiotics have marked a major victory of mankind in the battle against infectious diseases. However, after 90 years, the antibiotics are now losing their old time glory: Bacteria acquire resistance against antibiotics and become unbridled. We must control the use of antibiotics, meanwhile, we need new antibiotics, which can sufficiently eliminate the invaders without hurting the "good" bacteria. Therefore, cyclic di-AMP, an important, recently discovered signaling molecule in Gram-positive bacteria, has come to our sight. Our project is to build a screening system targeting c-di-AMP, which could be applied in novel-drug screening. With this system, the level of c-di-AMP in the cell can be visualized and measured. |
<html></div></html> | <html></div></html> | ||
Line 49: | Line 64: | ||
https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | ||
- | documented all our 17 | + | documented all our 17 BioBricks, including new ones, modified ones and improved ones. |
<html><div style="margin-left:60px"></html> | <html><div style="margin-left:60px"></html> | ||
- | For all our parts, we have | + | For all our parts, we have accomplished: |
https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | ||
Line 62: | Line 77: | ||
https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | ||
- | + | acknowledgment of sources and references | |
<html></div></div><div style="padding:0 20px;border-left:60px solid #c0c0c0;width:900px"></html> | <html></div></div><div style="padding:0 20px;border-left:60px solid #c0c0c0;width:900px"></html> | ||
Line 77: | Line 92: | ||
https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | ||
- | documented the characterization of this part in the 'Main Page' of that Part's/Device's Registry entry. | + | documented the characterization of this part in the 'Main Page' of that Part's/Device's Registry entry. submitted new parts to the iGEM Parts Registry. |
<html><div style="margin-left:60px"></html> | <html><div style="margin-left:60px"></html> | ||
Line 90: | Line 105: | ||
https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | ||
- | + | acknowledgment of sources and references | |
<html></div></html> | <html></div></html> | ||
Line 108: | Line 123: | ||
https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | ||
- | improved the function of an existing BioBrick Part or Device (created by another team or your own institution in a previous year), entered this information in the 'Experience' section of that Parts's Registry entry), | + | improved the function of an existing BioBrick Part or Device (created by another team or your own institution in a previous year), entered this information in the 'Experience' section of that Parts's Registry entry), created a new registry page for the improved part, and submit this part to the iGEM Registry. See [[Team:Goettingen/Parts|Parts]] |
<html><div style="margin-left:60px"></html> | <html><div style="margin-left:60px"></html> | ||
Line 121: | Line 136: | ||
https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | ||
- | + | acknowledgment of sources and references | |
<html></div></html> | <html></div></html> | ||
https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | https://static.igem.org/mediawiki/2013/2/24/Goe-%E2%88%9A.JPEG | ||
- | collaborated with Team Groningen in | + | collaborated with Team Groningen in the Netherlands, and provided two soil samples for Team Norwich. |
<html></div></html> | <html></div></html> | ||
- | |||
- | |||
- | Best | + | <br /> |
+ | ===We apply for=== | ||
+ | |||
+ | <br /> | ||
+ | Best BioBrick Measurement Approach | ||
- | + | Best Model | |
- | The progress in the development of new antibiotics has been very slow during the last decades, leaving many strains of bacteria untreatable. This problem has been growing ever since the invention of antibiotics but has now become a real threat to millions of people around the world. This Threat we want to tackle with a new approach: We develop a system to test substances on a new target, | + | The progress in the development of new antibiotics has been very slow during the last decades, leaving many strains of bacteria untreatable. This problem has been growing ever since the invention of antibiotics but has now become a real threat to millions of people around the world. This Threat we want to tackle with a new approach: We develop a system to test substances on a new target, c-di-AMP. |
C-di-AMP was discovered to be an essential signaling molecule in Gram-positive bacteria including the pathogens ''Streptococcus pneumoniae, Staphylococcus aureus'' and ''Listeria monocytogenes''. Both loss and overproduction of c-di-AMP have detrimental effects on cell growth, cell wall synthesis and propagation. | C-di-AMP was discovered to be an essential signaling molecule in Gram-positive bacteria including the pathogens ''Streptococcus pneumoniae, Staphylococcus aureus'' and ''Listeria monocytogenes''. Both loss and overproduction of c-di-AMP have detrimental effects on cell growth, cell wall synthesis and propagation. | ||
- | '''Best | + | '''Best BioBrick Measurement Approach: ''' |
Thus, the diadenylate cyclase (DAC) which catalyses the condensation reaction of 2 ATP molecules to c-di-AMP is the key factor for c-di-AMP homeostasis. We are convinced that the DAC protein is a very promising target for the development of highly specific antibiotic substances which exclusively act on Gram-positive bacteria and are not harming Gram-negative ones, including the gut bacterium ''Escherichia coli'' as well as humans. We characterized the DAC ''in vivo'' and ''in vitro''. Here, we introduce a truncated but functional DAC, which localizes to the cytosol and can easily be purified. Furthermore, we obtained protein crystals and the protein structure by X-ray diffraction analysis. For the first time ever the 3D structure for this cyclase, which is conserved among all important Gram-positive bacteria, was resolved. This structure will be an important starting point for bioinformatic docking studies (BBa_K1045003) | Thus, the diadenylate cyclase (DAC) which catalyses the condensation reaction of 2 ATP molecules to c-di-AMP is the key factor for c-di-AMP homeostasis. We are convinced that the DAC protein is a very promising target for the development of highly specific antibiotic substances which exclusively act on Gram-positive bacteria and are not harming Gram-negative ones, including the gut bacterium ''Escherichia coli'' as well as humans. We characterized the DAC ''in vivo'' and ''in vitro''. Here, we introduce a truncated but functional DAC, which localizes to the cytosol and can easily be purified. Furthermore, we obtained protein crystals and the protein structure by X-ray diffraction analysis. For the first time ever the 3D structure for this cyclase, which is conserved among all important Gram-positive bacteria, was resolved. This structure will be an important starting point for bioinformatic docking studies (BBa_K1045003) | ||
Line 148: | Line 165: | ||
'''Best Model Approach: ''' | '''Best Model Approach: ''' | ||
- | To test an antibiotic on the new target, we isolated (as mentioned above) the truncated DAC and did activity measurements on it. Using this data, we can now screen thousands of substances for impacts on the function of the DAC (''in silico'' and ''in vitro'' screening). Furthermore, we created in vivo reporter systems in ''E. coli'', giving us the ability to sense the amount of c-di-AMP inside the cells, as well as to find possible inhibitors or competitors for c-di-AMP. Last but not least, the combination of the two: An ''in vivo'' reporter system with the DAC expressed in the same cell will be the c-di-AMP pathway from Gram-positive bacteria, reconstructed in ''E. coli''. This way, it will be ready to screen for substances lethal to it´s Gram-positive relatives, without harming our host. In consequence, our model will facilitate the search for novel antibiotics hitting a novel target in Gram-positive bacteria. | + | To test an antibiotic on the new target, we isolated (as mentioned above) the truncated DAC and did activity measurements on it. Using this data, we can now screen thousands of substances for impacts on the function of the DAC (''in silico'' and ''in vitro'' screening). Furthermore, we created ''in vivo'' reporter systems in ''E. coli'', giving us the ability to sense the amount of c-di-AMP inside the cells, as well as to find possible inhibitors or competitors for c-di-AMP. Last but not least, the combination of the two: An ''in vivo'' reporter system with the DAC expressed in the same cell will be the c-di-AMP pathway from Gram-positive bacteria, reconstructed in ''E. coli''. This way, it will be ready to screen for substances lethal to it´s Gram-positive relatives, without harming our host. In consequence, our model will facilitate the search for novel antibiotics hitting a novel target in Gram-positive bacteria. |
- | ==About our parts== | + | <br /> |
+ | ===About our parts=== | ||
We have two new parts built, namely: [http://partsregistry/Part:BBa_K1045003 BBa_K1045003],[http://partsregistry/Part:BBa_K1045017 BBa_K1045017] | We have two new parts built, namely: [http://partsregistry/Part:BBa_K1045003 BBa_K1045003],[http://partsregistry/Part:BBa_K1045017 BBa_K1045017] |
Latest revision as of 19:34, 4 October 2013